肝脏 ›› 2025, Vol. 30 ›› Issue (11): 1546-1548.

• 其他肝病 • 上一篇    下一篇

糖皮质激素联合甘露醇治疗淤胆型肝炎的早期疗效评估

董晓锋, 梁栋   

  1. 450042 郑州 联勤保障部队第九八八医院感染科
  • 收稿日期:2024-09-11 出版日期:2025-11-30 发布日期:2026-02-09
  • 通讯作者: 梁栋,Email:324256854@qq.com

Early efficacy evaluation of glucocorticoids combined with mannitol in the treatment of cholestatic hepatitis

DONG Xiao-feng, LIANG Dong   

  1. Department of Infectious Disease, the NO. 988 Hospital of Joint Logistic Support Force, Zhengzhou 450042, China
  • Received:2024-09-11 Online:2025-11-30 Published:2026-02-09
  • Contact: LIANG Dong,Email:324256854@qq.com

摘要: 目的 研究糖皮质激素联合甘露醇注射液治疗淤胆型肝炎患者的临床疗效。方法 将我院2018年3月至2023年12月收治的80例淤胆型肝炎患者分为治疗组(36例)和对照组(44例),对照组给予保肝、降黄、治疗原发病及对症治疗,治疗组在对照组基础上给予糖皮质激素联合甘露醇注射液治疗。观察两组治疗前后肝功能指标改善情况、总体有效率及不良反应情况。结果 两组治疗前肝功能相关指标水平差异无统计学意义(P>0.05),治疗后治疗组、对照组TBil、DBil、ALT、AST、ALP、GGT、TBA分别为(98.2±5.9)μmol/L、(52.6±5.2) μmol/L、(40.1±3.9) U/L、(39.7±2.8) U/L、(98.8±12.5) U/L、(101.2±5.1)U/L、(28.7±8.9) μmol/L和(116.6±7.9) μmol/L、(71.1±6.4) μmol/L、(45.4±4.3) U/L、(44.8±3.7) U/L、(123.7±14.9) U/L、(128.5±9.3) U/L、(49.8±11.7) μmol/L,两组指标均较治疗前明显下降(P<0.05),其中治疗组TBil、DBil、ALP、GGT、TBA下降幅度明显大于对照组(P<0.05),ALT、AST下降幅度差异无统计学意义(P>0.05)。治疗组与对照组治疗总体有效率分别为83.3%和68.2%,差异有统计学意义(P<0.05)。治疗组10例患者使用激素后出现兴奋、失眠,5例患者使用甘露醇加压静滴后出现静脉血管刺激不适,2例红肿,但均坚持至治疗结束。结论 小剂量、短疗程糖皮质激素联合甘露醇注射液治疗淤胆型肝炎早期患者可明显改善其肝功能指标,缩短病程,改善预后,且不良反应可控,可尝试在临床积极应用。

关键词: 淤胆型肝炎, 糖皮质激素, 甘露醇, 总胆红素, 总胆汁酸

Abstract: Objective To investigate the clinical efficacy of glucocorticoid combined with mannitol injection in the treatment of patients with cholestatic hepatitis. Methods 80 patients with cholestatic hepatitis admitted to our hospital from March 2018 to December 2023 were divided into a treatment group (36 cases) and a control group (44 cases). The control group received liver protection, jaundice reduction, treatment of the primary disease, and symptomatic treatment. The treatment group received glucocorticoid combined with mannitol injection on the basis of treatment in the control group. The improvement of liver function indicators, overall effective rate, and adverse reactions before and after treatment were observed in both groups. Results There was no significant difference in the levels of liver function related indicators between the two groups before treatment (P>0.05). After treatment, the levels of TIBL, DBil, ALT, AST, ALP, GGT, and TBA in the treatment group and the control group were (98.2±5.9) μmol/L、(52.6±5.2) μmol/L、(40.1±3.9) U/L、(39.7±2.8) U/L、(98.8±12.5) U/L、(101.2±5.1) U/L、(28.7±8.9) μmol/L, and (116.6± 7.9 )μmol/L、(71.1±6.4) μmol/L、(45.4±4.3) U/L、(44.8±3.7) U/L、(123.7±14.9) U/L、(128.5±9.3) U/L、(49.8±11.7) μmol/L, all of which showed a significant decrease compared to before treatment (P<0.05). Among them, the treatment group showed significantly higher levels of TBil, DBil, ALP, GGT, and TBA than the control group (P<0.05), while there was no significant difference in the decrease of ALT and AST (P>0.05); The overall effective rates of the treatment group and the control group were 83.3% and 68.2%, respectively, with a statistically significant difference (P<0.05); Ten patients in the treatment group experienced excitement and insomnia after using hormones, while five patients experienced discomfort due to venous vessel stimulation after using mannitol for pressurized intravenous infusion, two patients developed redness and swelling, all of them persisted until the end of treatment. Conclusion The combination of low-dose and short course glucocorticoids and mannitol injection can significantly improve liver function indicators, shorten the course of disease, improve prognosis, and have controllable adverse reactions in patients with early cholestatic hepatitis. It can be actively applied in clinical practice.

Key words: Cholestatic hepatitis, Corticosteroids, Mannitol, Total bilirubin, Total bile acids